Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
02 nov. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Blood Collection Devices Market Worth Nearly $14 Billion by 2030 - Exclusive Report by The Insight Partners
23 oct. 2023 09h35 HE
|
The Insight Partners
Pune, India, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Blood collection devices help in safe withdrawal of blood. Blood is collected from donor to perform various diagnostic tests. Needles & Syringes,...
Non-small Cell Lung Cancer Market is Projected to Boost by 2032, Predicts DelveInsight | Key Companies Working in Space - AstraZeneca, BMS, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly, Immutep, Sanofi, GlaxoSmithKline
27 juil. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 27, 2023 (GLOBE NEWSWIRE) -- Non-small Cell Lung Cancer Market is Projected to Boost by 2032, Predicts DelveInsight | Key Companies Working in Space - AstraZeneca, BMS, AbbVie,...
BioNTech und OncoC4 starten zulassungsrelevante Phase-3-Studie mit BNT316/ONC-392-Programm bei metastasiertem, nicht-kleinzelligem Lungenkarzinom
29 juin 2023 06h45 HE
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie für nicht-kleinzelliges Lungenkarzinom ist ein wichtiger erster Schritt in BioNTechs und OncoC4s strategischer Kollaboration, die im März 2023...
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
29 juin 2023 06h45 HE
|
BioNTech SE
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate...
BioNTech und OncoC4 präsentieren positive Phase-1/2-Daten für Antikörperkandidaten BNT316/ONC-392 bei schwer behandelbarem nicht-kleinzelligen Lungenkarzinom auf ASCO-Jahrestagung
02 juin 2023 06h45 HE
|
BioNTech SE
BNT316/ONC-392 ist ein innovativer monoklonaler anti-CTLA-4-Antikörperkandidat, der gemeinsam von BioNTech und OncoC4 als Mono- oder Kombinationstherapie zur Behandlung verschiedener solider...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
02 juin 2023 06h45 HE
|
BioNTech SE
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications,...
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
16 mars 2023 16h04 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
23 févr. 2023 08h01 HE
|
Ocean Biomedical, Inc.
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and...
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
01 févr. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...